Medical Futures Inc.

Medical Futures Inc.
Norgine

Norgine

April 28, 2011 12:53 ET

Medical Futures Inc. and Norgine Announce the Launch of MOVIPREP®, a Bowel Cleansing Preparation in Canada

RICHMOND HILL, ONTARIO--(Marketwire - April 28, 2011) - "The launch of MOVIPREP® underlines Medical Futures' commitment to the prevention and treatment of gastrointestinal diseases," said Colin Campbell, Medical Futures' CEO.

Commenting on the launch Peter Stein, Norgine's CEO, said: "We are delighted that our collaboration with Medical Futures has reached this important milestone. We have been impressed by Medical Futures' commitment to the bringing of MOVIPREP® to Canada, by their in-depth knowledge of the Canadian regulatory requirements and by their strong presence in the Canadian gastroenterology market."

MOVIPREP® is marketed by Norgine in Europe, in the USA by its partner Salix Pharmaceuticals and is under development in Japan by Anjinomoto.

About Norgine

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2009, Norgine's net product sales were €253 million, the 23rd year of double-digit growth at constant exchange rates. The company employs over 1,200 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in areas such as gastroenterology, hepatology and supportive care. The company currently markets a range of products in various markets in its key therapeutic areas e.g., MOVICOL® for the treatment of constipation and faecal impaction, MOVIPREP® a bowel cleansing preparation, KLEAN-PREP® for bowel preparation prior to colonoscopy, XIFAXAN® for the treatment of travellers diarrhoea and hepatic encephalopathy and ORAMORPH® for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, Wales and Dreux in France.

About Medical Futures

Medical Futures Inc. is a niche pharmaceutical company that distributes both pharmaceutical and natural therapeutic products into the North American marketplace. Founded in 2000, this privately held company is dedicated to advancing the quality of life of all North Americans. The current product offering includes:

Florastor®and FlorastorKids®: The number one probiotic worldwide in terms of clinical evidence, efficacy, sales and distribution. Florastor helps provide effective relief of diarrhea across multiple indications including antibiotic associated and acute infectious for both adults and children.

Iberogast®: Used for over 45 Years in Europe with over 40 clinical trials for gastrointestinal conditions such as irritable bowel syndrome and dyspepsia. Iberogast provides proven relief of heartburn, bloating, cramping nausea and abdominal pain.

Proferrin®: Canada's only heme based iron supplement. Heme iron has high absorption and low side effects.

Pegalax™: Clinically proven relief of occasional constipation. Safe and effective worldwide for more than 10 years.

Mutaflor®: A unique and powerful probiotic providing relief from constipation and diarrhea. Studied in Europe for over 80 years with clinical trials showing improvement in gastrointestinal symptoms associated with conditions such as ulcerative colitis, Crohn's disease and irritable bowel syndrome.

Purfem™ Probiotic: A novel probiotic containing 2 strains of lactobacillus in a vaginal ovule that renews a woman's intimate freshness and comfort.

Contact Information